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Background. Strategies to dissect phenotypic and genetic heterogeneity of major depressive disorder (MDD) have
mainly relied on subphenotypes, such as age at onset (AAO) and recurrence/episodicity. Yet, evidence on whether
these subphenotypes are familial or heritable is scarce. The aims of this study are to investigate the familiality of
AAO and episode frequency in MDD and to assess the proportion of their variance explained by common single nucleo-
tide polymorphisms (SNP heritability).
Method. For investigating familiality, we used 691 families with 2–5 full siblings with recurrent MDD from the DeNt
study. We ﬁtted (square root) AAO and episode count in a linear and a negative binomial mixed model, respectively,
with family as random effect and adjusting for sex, age and center. The strength of familiality was assessed with intra-
class correlation coefﬁcients (ICC). For estimating SNP heritabilities, we used 3468 unrelated MDD cases from the
RADIANT and GSK Munich studies. After similarly adjusting for covariates, derived residuals were used with the
GREML method in GCTA (genome-wide complex trait analysis) software.
Results. Signiﬁcant familial clustering was found for both AAO (ICC = 0.28) and episodicity (ICC = 0.07). We calculated
from respective ICC estimates the maximal additive heritability of AAO (0.56) and episodicity (0.15). SNP heritability of
AAO was 0.17 (p = 0.04); analysis was underpowered for calculating SNP heritability of episodicity.
Conclusions. AAO and episodicity aggregate in families to a moderate and small degree, respectively. AAO is under
stronger additive genetic control than episodicity. Larger samples are needed to calculate the SNP heritability of episo-
dicity. The described statistical framework could be useful in future analyses.
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Introduction
Despite extensive research in the ﬁeld, the genetic
architecture of major depressive disorder (MDD)
remains highly elusive. Eight genome-wide association
studies (GWAS) of MDD have been published
(Sullivan et al. 2009; Lewis et al. 2010; Muglia et al.
2010; Rietschel et al. 2010; Kohli et al. 2011; Shi et al.
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2011; Shyn et al. 2011; Wray et al. 2012), with only one
locus of genome-wide signiﬁcance (Kohli et al. 2011). A
recently published mega-analysis of GWAS studies in
MDD by the Psychiatric Genomics Consortium (PGC)
failed to identify any genome-wide signiﬁcant ﬁndings
(PGC, 2013). Phenotypic and genetic heterogeneity
have been pinpointed as partly responsible for these
as yet unfruitful investigations.
Promising strategies to dissect MDD heterogeneity
have mainly relied on subphenotypes such as age at
onset (AAO) and recurrence/episodicity. Many
researchers have used samples enriched in recurrent
and early-onset forms (Shi et al. 2011; PGC, 2013) as
these clinical subtypes are most consistently associated
with higher familial aggregation and heritability of
MDD (Sullivan et al. 2000). Other studies have directly
focused on genetic correlates of the speciﬁc subpheno-
types (AAO, episode frequency), analyzed as continu-
ous traits (Power et al. 2012; Ferentinos et al. 2014). Yet,
evidence on whether these subphenotypes are per se
familial or heritable is scarce in MDD. Small or nil her-
itabilities for AAO and episode count, respectively,
were reported in a small sample of 176 female twin
pairs with MDD (Kendler et al. 1992).
Classical methods to estimate the narrow-sense heri-
tability of quantitative traits, i.e. the percentage of
phenotypic variance explained by additive genetic ef-
fects (VA/VP), rely on observed familial aggregation or
phenotypic resemblance among relatives (parents–off-
spring, full-siblings, half-siblings, twins), usually on
the basis of non-veriﬁable assumptions (random mat-
ing, absence of signiﬁcant dominance, epistatic, and
shared environmental effects or gene–environment cor-
relation and interaction) (Visscher et al. 2008; Tenesa &
Haley, 2013). The recently developed genome-wide
complex trait analysis (GCTA) software (Yang et al.
2011) employs observed genetic covariance calculated
from GWAS data in restricted maximum-likelihood lin-
ear mixed models (GREML) for unrelated subjects to es-
timate the percentage of phenotypic variance explained
by common single nucleotide polymprphisms (i.e. the
SNP heritability of a trait), without having to rely on
those assumptions; SNP heritability estimates provide
a lower bound on the total narrow-sense heritability
of a phenotype (Zaitlen & Kraft, 2012).
Since subtyping is increasingly used in MDD genetic
research, more evidence on the familial aggregation
and heritability of subphenotypes, such as AAO and
episodicity (which together reﬂect the disorder’s tem-
poral proﬁle) would be valuable. The aims of this
study are, therefore: ﬁrst, to investigate the familiality
of AAO and episode frequency of MDD (studied as
quantitative/continuous phenotypes) and thereby
infer estimates of their narrow-sense heritability
(i.e. the proportion of the variance of AAO and episode
frequency in MDD cases explained by additive genetic
effects); second, to assess the SNP heritability of these
subphenotypes in unrelated subjects with MDD.
Subjects and method
Samples
For the investigation of familial effects, we used sub-
jects from the DeNt (Depression Network) affected sib-
lings study (Farmer et al. 2004; McGufﬁn et al. 2005;
Breen et al. 2011), which comprises cases of recurrent
depression fulﬁlling DSM-IV and/or ICD-10 criteria
of at least moderate severity ascertained from three
UK clinical sites (London, Cardiff, Birmingham), four
other European sites (Aarhus, Bonn, Dublin,
Lausanne) and a site in St Louis, USA. One familial
cluster of affected full siblings was identiﬁed in each
family; in extended families, we used only the sibship
including the proband or the sibship with most com-
plete data on AAO and episode frequency. A total of
1498 subjects from 691 families with 2–5 affected full
siblings were extracted for statistical analysis (Table 1).
For the assessment of the SNP heritability of AAO,
we used 3468 genotyped, unrelated MDD cases with
complete data on age and AAO; 2695 cases were
obtained from the RADIANT study, i.e. from the
Depression Case-Control (DeCC) (N = 1023), DeNt
(N = 843), GSK Case-Control (N = 140) and GENDEP
(N = 689) studies, while 773 cases were obtained from
the GSK Munich study. The DeCC study includes
cases of recurrent depression of at least moderate
severity ascertained from three UK sites (London,
Cardiff, Birmingham) (Cohen-Woods et al. 2009). One
proband from each DeNt family was genotyped and
also included in the RADIANT study. The GSK
Case-Control study includes cases of recurrent de-
pression collected in Bonn and Lausanne in collabor-
ation with GSK, using exactly the same protocol as
the DeNt study. Cases from GENDEP (Uher et al.
2009), a pharmacogenetic study, were ascertained
from various sites across Europe (London, Brussels,
Mannheim, Bonn, Brescia, Aarhus, Ljubljana, Poznan,
Zagreb); while recurrence was not a requirement,
59.5% of GENDEP cases suffered from recurrent MDD.
The GSK Munich sample includes cases of recurrent de-
pression of at least moderate severity recruited for a
case-control study in the Munich area in collaboration
with GSK (Tozzi et al. 2008; Muglia et al. 2010). To calcu-
late the SNP heritability of episodicity, we extracted a
subset of 2368 cases with recurrent MDD from the
total sample with complete data on episode count (as
well as on age and AAO), i.e. 994 DeCC, 833 DeNt,
139 GSK Case-Control and 402 GSK Munich cases.
In the RADIANT studies, only adults of European
ancestry were recruited. Subjects were excluded if
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there was a history or family history (in ﬁrst- or
second-degree relatives) of schizophrenia, schizoaf-
fective disorder or bipolar disorder, if they had ex-
perienced mood-incongruent psychotic symptoms,
or if mood symptoms were solely related to alcohol
or substance misuse or only secondary to medical ill-
ness or medication. Inclusion/exclusion criteria in the
GSK Munich study were identical to those used in
the DeCC and DeNT studies, except that subjects
with a family history of bipolar disorder were not
excluded. Therefore, we removed the latter from the
analyses.
All subjects were interviewed with the Schedules for
Clinical Assessment in Neuropsychiatry (SCAN; Wing
et al. 1990), focusing on their worst and second-worst
episodes of depression. AAO was recorded in SCAN
items 1.016, 1.046–1.048 and 6.025; episode count was
recorded in SCAN items 1.053 and 6.030. Family his-
tory of MDD in ﬁrst-degree relatives was also extracted
from SCAN item 1.045. All study participants pro-
vided written informed consent and approval was
obtained from local ethics committees.
Whole-genome genotyping in the RADIANT sample
was performed using the Illumina HumanHap610-
Quad BeadChip. Genotyping in the GSK Munich sam-
ple was performed on the Illumina Human-Hap550K
platform. Stringent quality control procedures were ap-
plied to individual and SNP data in both studies leaving
a total of 471 581 and 511 503 SNPs, respectively, ﬁnally
eligible for analysis (for full details see Lewis et al. 2010;
Muglia et al. 2010). The two samples were then merged
using PLINK v. 1.07 (Purcell et al. 2007) and taking into
account ﬂipped strands issues; the merged sample, in-
cluding 427 946 SNPs shared by the original samples,
was ﬁnally used with GCTA software.
Ethical standards
The authors assert that all procedures contributing to
this work comply with the ethical standards of the rel-
evant national and institutional committees on human
experimentation and with the Helsinki Declaration of
1975, as revised in 2008.
Method
Statistical modeling
Descriptive statistics were used to investigate the dis-
tributions of all variables in the DeNt families and gen-
otyped case sets. AAO was analyzed as a continuous
variable in linear mixed models; however, as it had a
positively skewed distribution, it was ﬁrst transformed
to square root AAO (sqrtAAO) to approach normality.
Lifetime number of depressive episodes was a count
variable; therefore, we considered Poisson and nega-
tive binomial (NB) models as most suitable in sub-
sequent analyses. Episode frequency was deﬁned as
the rate of the lifetime number of depressive episodes
over the total duration of MDD (=age – age at onset).
As its distribution was also highly skewed, a natural
logarithm transformation (lnepisfreq) was used for
this dependent variable in ﬁtted linear models.
Investigation of familial effects
To investigate the familiality of AAO in the DeNt sib-
lings sample, we initially ﬁtted a three-level linear
mixed model (LMM) with sqrtAAO as the dependent
variable, sex as ﬁxed effect covariate and center and
family as random effects (subjects nested within fam-
ilies; families nested within centers). Familiality of
sqrtAAO was documented if the variance of the ran-
dom effect of family was signiﬁcantly greater than
zero. The strength of the familial effect was measured
by calculating the family-level residual intraclass corre-
lation coefﬁcient (ICC) and its conﬁdence interval (CI)
(Wynants et al. 2013); the residual ICC represents the
proportion of the residual variance of sqrtAAO (after
taking into account the effect of ﬁxed covariates – in
this case sex) accounted for by family membership.
As it has been suggested that AAO can be considered
a censored variable and siblings correlated in chrono-
logical age will also tend to be correlated in AAO
(Schulze et al. 2006), we also ﬁtted a model additionally
including age as a ﬁxed effects covariate and calculated
the signiﬁcance of the family random effect as well as
the ICC. Analyses were implemented with the Stata
v. 13 (StataCorp, 2013) mixed command.
To investigate the familiality of episodicity in the
DeNt siblings sample, we employed two methods. In
the ﬁrst method, we ﬁtted a two-level NB generalized
linear mixed model (GLMM) with episode count as
the dependent variable, sex, age and center as ﬁxed ef-
fects covariates, (ln)MDD duration as offset variable
(this reﬂects the time over which the count response is
generated) and family as random effect (subjects nested
within families; families nested within centers). Analysis
was performed with the Stata v. 13 menbreg command,
with adaptive Gauss–Hermite quadrature as integration
Table 1. Composition of the DeNt affected full-siblings sample
Number of affected
siblings per family
Number of
families
Number of affected
individuals (%)
2 600 1200 (80.1)
3 73 219 (14.6)
4 11 44 (2.9)
5 7 35 (2.3)
Total 691 1498 (100.0)
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method (seven integrations points) (Bolker et al. 2009).
Familiality of episodicity was similarly assessed by test-
ing whether the variance of the family random effect
was signiﬁcantly greater than zero. The family-level
ICC for episodicity and its CI, i.e. the proportion of
the variance of episode frequency explained by family
membership after taking into account the effect of cen-
ter, were ﬁnally calculated in a ‘reduced’ version of
our model, i.e. one without any subject-level covariates
(sex, age), on the basis of recent work formulating an
ICC in GLMMs for overdispersed count data (see
Supplementary Method) (Carrasco, 2010). We also
used a second method to investigate the familiality of
episodicity as it was previously used to investigate the
familial variation of episode frequency in bipolar dis-
order (Fisfalen et al. 2005); we ﬁtted a three-level
LMM with lnepisfreq as the dependent variable, sex
and age as ﬁxed effects covariates, and center and fam-
ily as random effects (subjects nested within families;
families nested within centers). Familiality of lnepisfreq
was similarly investigated. A family-level residual ICC
and its CI were ﬁnally calculated.
Inference of narrow-sense heritability from
familiality
Observed phenotypic covariance between relatives
(familiality) can be partitioned to causal genetic and
environmental covariance components; for full sib-
lings, phenotypic covariance is the sum of half their ad-
ditive genetic variance plus a quarter of the dominance
variance plus the shared environment variance (the
contribution of epistatic interactions is ignored)
(COVFS = 1/2VA + 1/4VD + VC) and their phenotypic cor-
relation is the ratio of their phenotypic covariance by
the phenotypic variance (ICC =COVFS/VP) (Falconer &
Mackay, 1996; Tenesa & Haley, 2013). Therefore, twice
the full-siblings correlation (2 × ICC) is a good estimate
of narrow-sense heritability (VA/VP) only when domi-
nance and shared environment contributions are
assumed negligible and can hence provide an upper
bound estimate of heritability (‘maximal heritability’).
Assessment of SNP heritabilities
To investigate the SNP heritability of AAO in genotyped
cases (mergedRADIANTandGSKMunich samples),we
ﬁrst ﬁtted a LMM with sqrtAAO as the dependent vari-
able, sex and study as ﬁxed-effects covariates and center
as random effect; we then saved the residuals. Analysis
was performed with the Stata v. 13 mixed command.
The model residuals were then used to calculate the
SNP heritability of AAO with the GREML method in
GCTA software, using 10 principal components as cov-
ariates, a genetic relationship matrix (GRM) cut-off of
0.025 and a minor allele frequency (MAF) cut-off of 0.01.
To investigate the SNP heritability of episodicity in
genotyped cases, we employed two methods to obtain
an adjusted episodicity variable. In the ﬁrst method,
we ﬁtted a NB GLMM (Stata v. 13 menbreg command)
with episode count as the dependent variable, sex, age
and study as ﬁxed-effects covariates, center as random
effect, (ln)MDD duration as offset variable, and saved
episode frequency deviance residuals. As their distri-
bution was slightly skewed, we rank-normalized
them using Blom’s formula (Blom, 1958). The rank-
normalized adjusted episodicity residuals were then
used to calculate the SNP heritability of episodicity
with GCTA software, using the same speciﬁcations as
above. In the second method, we ﬁtted a LMM with
lnepisfreq as the dependent variable, sex, age and
study as ﬁxed-effects covariates, and center as random
effect. We then saved the residuals, rank-normalized
them using Blom’s formula, and ﬁnally used them
with GCTA software as previously described.
We ﬁnally estimated the SNP heritabilities of AAO
and episodicity that could be detected with a power
of 80% (Visscher et al. 2014).
Results
Demographic and clinical characteristics of DeNt
siblings and genotyped cases (RADIANT and GSK
Munich samples and their merge) are shown in
Table 2 and Supplementary Table S1. Frequency distri-
butions (histograms) of age, AAO, episode count and
episode frequency in genotyped cases (Fig. 1,
Supplementary Fig. S2) and in DeNT siblings
(Supplementary Fig. S1) were plotted.
Familiality of AAO and episode frequency
In the LMM for sqrtAAO in the DeNt sample (N =
1403), the variance of the family random effect was
signiﬁcantly greater than zero; the family-level residual
ICC was 0.278 (95% CI 0.185–0.395) (Table 3,
Supplementary Table S2a). When we additionally
included age as a ﬁxed-effects covariate in our model,
we obtained a lower but still signiﬁcant family-level
residual ICC of 0.229 (95% CI 0.140–0.354) (Table 3,
Supplementary Table S2b).
Our NB GLMM for episodicity in the DeNt sample
(N = 878) ﬁtted the observed data better than a corre-
sponding Poisson model (Supplementary Table S3).
The variance of the family random effect was signiﬁ-
cantly greater than zero in both the ‘full’ and the
‘reduced’ model (Table 3, Supplementary Table S3).
The family-level ICC for episodicity and its CI
were calculated on our ‘reduced’ model (online
Supplementary Table S3b). We recorded the overdis-
persion (alpha) parameter and the variance of the
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family random effect; we also calculated center vari-
ance and episode frequency marginal expectation
over families. The family-level ICC for episodicity
was ﬁnally estimated with the Stata v. 13 nlcom com-
mand using all aforementioned parameter estimates
on the basis of Carrasco’s formulae (full details in
Supplementary Method); ICC = 0.074, S.E. = 0.012 (95%
CI 0.051–0.096).
In the LMM for lnepisfreq in the DeNt sample, the
variance of the family random effect was signiﬁcantly
greater than zero; the family-level residual ICC was
0.167 (95% CI 0.089–0.292) (Table 3, Supplementary
Table S4).
Calculation of ‘maximal heritability’ from
familiality (ICC estimates)
Assuming dominance and shared environment vari-
ance components are negligible, narrow-sense herita-
bility reaches its upper limit (‘maximal heritability’),
which is twice the ICC estimate. Maximal heritability
estimates obtained are 0.46 and 0.56 for AAO
Table 2. Demographic and clinical characteristics of DeNT siblings and genotyped cases (merged RADIANT and GSK Munich samples)
DeNt siblings (N = 1498) Genotyped cases (N = 3468)
Sex (females) 73.4% (N = 1498) 69.8% (N = 3468)
Age (yr) 44.8 ± 11.9 (18–80) (N = 1498) 46.2 ± 12.7 (18–87) (N = 3468)
Age at onset (yr) 22.8 ± 11.2 (0–74) (N = 1403) 27.6 ± 13.2 (1–78) (N = 3468)
MDD duration (yr) 22.1 ± 12.9 (0–68) (N = 1403) 18.7 ± 13.7 (0–71) (N = 3468)
Episode count 5.5 ± 8.2 (2–100) (N = 898) 4.0 ± 4.7 (2–50) (N = 2368)
Episode frequency (episodes/yr) 0.32 ± 0.36 (0.03–3.0) (N = 878) 0.29 ± 0.35 (0.03–3.0) (N = 2368)
Quantitative data are presented as mean±S.D. (range).
Fig. 1. Frequency distributions (histograms) of (a) age, (b) age at onset, (c) episode count and (d) episode frequency in
genotyped cases (merged RADIANT and GSK Munich samples).
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(depending on whether age was included as covariate
in the model or not, respectively) and 0.15 and 0.33 for
episodicity (depending on the method of calculation
used, NB GLMM or LMM, respectively) (Table 4).
SNP heritability of AAO and episode frequency
In the LMM for sqrtAAO (N = 3468), we saved the resi-
duals and then used them with the GREML procedure
in GCTA software (Supplementary Table S5). The SNP
heritability of sqrtAAO was calculated at 0.175 (S.E. =
0.104, p = 0.042).
In the NB GLMM of episodicity (N = 2368), we saved
episode frequency deviance residuals, rank-normalized
themand then used themwith theGREMLprocedure in
GCTA software (Supplementary Table S6). The SNP
heritability of episodicity was estimated at 0.092 (S.E. =
0.143, p = 0.260).
In the LMM of lnepisfreq, we saved lnepisfreq resi-
duals, rank-normalized them and then used them
with the GCTA software (Supplementary Table S7).
The SNP heritability of episodicity was estimated at
0.129 (S.E. = 0.148, p = 0.192).
Power was 0.8 to detect a SNP heritability of 0.25 for
AAO and 0.37 for episodicity.
Discussion
StratifyingMDDcasesbyAAOand recurrencehas exten-
sively been used in MDD genetic research as early-onset
and recurrent forms have been repeatedly associated
with higher familial aggregation and heritability of
MDD (Sullivan et al. 2000). However, there is paucity
of evidence regarding the familiality and heritability of
these MDD subphenotypes. By contrast, several other
subphenotypes, suchas symptomclusters ordimensions,
illness chronicity, personality traits, subaffective tem-
perament proﬁle or suicidality, have been shown to be
familial or heritable in MDD (Farmer et al. 2003; Dikeos
et al. 2004; Korszun et al. 2004; Mondimore et al. 2006;
McGirr et al. 2009; Aguiar Ferreira et al. 2013; Lai et al.
2013). Research into the genetic correlates of MDD sub-
phenotypes might help elucidate the pathogenesis of
MDDitself, given that it is phenotypicallyandgenetically
Table 3. Familiality of age at onset (AAO) and episodicity (two methods) in the DeNt affected full-siblings sample
Dependent variable Fixed effects Random effects Log-likelihood
Likelihood ratio test
(one-tailed χ2, df = 1) p value ICC
AAOa Sex Center, family −2108.30 29.32 <0.001 0.278d
Center −2122.96
Sex, age Center, family −2040.70 16.11 <0.001 0.229d
Center −2048.75
Episodicity (NB GLMM)b Sex, age, center Family −2310.95 80.47 <0.001 0.074e
None −2351.18
Episodicity (LMM)c Sex, age Center, family −1043.51 7.56 0.003 0.167d
Center −1047.29
a Linear mixed model with sqrtAAO as dependent variable.
b Negative binomial generalized linear mixed model (NB GLMM) with episode count as dependent variable and (ln)MDD
duration as offset variable.
c Linear mixed model (LMM) with ln(episode frequency) as dependent variable.
d Residual intraclass correlation coefﬁcient (ICC) calculated in the ‘full’ model with all covariates.
e ICC calculated in a model without subject-level covariates (‘reduced’ model, i.e. without sex and age) (Carrasco, 2010).
Table 4. Maximal heritability and SNP heritability estimates for
age at onset (AAO) and episodicity in MDD
Maximal heritability
(S.E.)a
SNP heritability
(S.E.)b
(sqrt)AAO 0.56 (0.11)
0.46 (0.11)c
0.17 (0.10)
–
Episodicityd 0.15 (0.02)
0.33 (0.10)
0.09 (0.14)
0.13 (0.15)
a Maximal heritabilities, calculated as twice the ICC
estimates from the DeNt affected full-siblings sample,
provide an upper limit to narrow-sense heritability.
b Single nucleotide polymorphism (SNP) heritabilities in
genotyped cases (merged RADIANT and GSK Munich
samples) provide a lower limit to narrow-sense heritability.
c Two estimates are provided depending on whether age
was included as covariate (lower line) in the model or not
(upper line).
d Two estimates are provided depending on the method
of calculation used (negative binomial generalized linear
mixed model, upper line; linear mixed model, lower line;
full details in text).
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heterogeneous. Furthermore, assuming that speciﬁc
subphenotypes are familial and heritable, one could
further explore their pleiotropic cross-phenotype genetic
correlations with other psychiatric disorders, medical
co-morbidities, personality traits or environmental stres-
sors (Lee et al. 2012; Solovieff et al. 2013).
This is the ﬁrst study to systematically investigate
the familiality of AAO and episodicity in MDD. The
two subphenotypes were analyzed as continuous traits
in mixed models, which allowed us to investigate their
familial clustering as well as the strength of intra-
familial correlations (ICC). To investigate the familial-
ity of episodicity, we ﬁtted two alternative models; a
NB GLMM for episode count and a simpler LMM for
ln(episode frequency). To calculate the ICC of episodi-
city in the ﬁrst model, we relied on a modiﬁcation of a
novel, recently published statistical formulation of an
ICC in GLMMs for overdispersed count data
(Carrasco & Jover, 2003, 2005; Carrasco, 2010).
Signiﬁcant familiality of both AAO and episodicity
was found in the DeNt affected full siblings sample.
A moderate proportion of the variance of (sqrt)AAO
(ICC = 0.23 with age adjustment and ICC = 0.28 with-
out age adjustment) was attributed to family member-
ship. Analysing episodicity, both methods produced
small ICC estimates (0.07 and 0.17, respectively).
However, since the number of depressive episodes is
a count variable, we consider the NB GLMM method
as more precise while the LMM method produces
inﬂated estimates.
The heritability of AAO and episodicity has, simi-
larly, rarely been studied; negligible estimates have
been reported for both subphenotypes in a small
female-only twin study (Kendler et al. 1992). We calcu-
lated an upper bound estimate of narrow-sense herita-
bility (‘maximal heritability’) of AAO and episodicity
in MDD from respective ICC estimates (Table 4). AAO
seems to be under stronger additive genetic control
than episodicity. Almost half of the variance of AAO
and the greatest part of the variance of episodicity are,
however, controlled by unique environment and stoch-
astic events. Yet, it is highly probable that gene–environ-
ment interactions, which are difﬁcult to disentangle
from unique environmental effects (Purcell, 2002;
Purcell & Sham, 2002), also contribute. Furthermore,
part of the additive genetic variance component of our
subphenotypes might in fact be contributed by genetic
control of environmental exposure (Kendler &
Karkowski-Shuman, 1997; Power et al. 2013).
We ﬁnally calculated the SNP heritability of the two
subphenotypes in unrelated MDD subjects with the
GREML procedure in GCTA software (Yang et al.
2011). This represents a lower limit to narrow-sense
heritability by estimating its component which is cap-
tured by common variants (Zaitlen & Kraft, 2012).
The SNP heritability of AAO was small but signiﬁcant
(0.17, p = 0.04). Estimates were non-signiﬁcant for epi-
sodicity (0.09 and 0.13, depending on the calculation
method) (Table 4); our study lacked power to detect
signiﬁcant and accurate estimates of this magnitude,
and much larger studies will be required (Visscher
et al. 2014).
Our AAO analysis used AAO as a continuous out-
come variable, but time-to-event (survival) analysis
could alternatively be used, which would also take
into account controls who have not manifested de-
pression at their age at interview; Cox regression mod-
els with random effects (also known as ‘shared-frailty
models’) have been described (Therneau &
Grambsch, 2000). Although such an analysis would
be feasible for genotyped subjects after adding con-
trols, few unaffected DeNt siblings were recruited
and we, therefore, opted for the analysis of AAO as a
quantitative trait in both datasets so that maximal heri-
tability and SNP heritability estimates thence derived
could be comparable.
Similarly, survival models for recurrent events
(multiple-failure data) could be used to analyze episo-
dicity (Baethge & Schlattmann, 2004). These models
allow for the effects of prior episode number, thera-
peutic interventions, episode duration, episode-
dependent covariates and unobserved heterogeneity
(frailty) in recurrence-prone tendency on the risk of fu-
ture recurrences (Kessing et al. 1999; Solomon et al.
2000) but could not be applied here as our data lacked
information on timing and duration of each episode.
Our NB model assumes that episodes are independent
events while a semi-parametric survival model would
withhold any assumptions about the distribution of
episode count; the results of our analysis might, there-
fore, be subject to some bias.
Two genome-wide studies of the genetic architecture
of AAO and episodicity in the RADIANT sample have
been published. A GWAS of AAO, analyzed with
three different methods, produced no genome-wide
signiﬁcant ﬁndings; a non-replicated genome-wide as-
sociation with the TUSC3 gene in young males with
an early AAO was recorded (Power et al. 2012). A pre-
liminary estimate of 0.55 (S.E. = 0.27, p = 0.02) for the
SNP heritability of (sqrt)AAO was also reported in this
study. This earlier estimate, which is substantially higher
than our current estimate, was based on AAO in UK
cases only, and unadjusted for the effects of sex and co-
hort (study and center); in the present study, we
adjusted sqrtAAO for these covariates, and extended
the analysis to MDD cases ascertained from sites across
Europe (including the UK) and one site in St Louis, USA.
Similarly, a GWAS of episodicity in the RADIANT sam-
ple produced only non-replicated ﬁndings of suggestive
signiﬁcance; interestingly, polygenic proﬁle analyses
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based on the PGC MDD and bipolar studies showed
that, in subjects with positive family history of MDD,
episodicity was predicted by both MDD and bipolar
polygenes (Ferentinos et al. 2014). These preliminary stu-
dies suggest that investigations in larger collaborative
samples are certainly warranted.
Bipolar disorder, unlike MDD, shows evidence of
the familiality and heritability of AAO and episodicity
subphenotypes. Available studies are either based on
extended families ascertained through bipolar pro-
bands and including relatives with major affective dis-
orders or on clusters of bipolar siblings. AAO is
familial, with reported ICC estimates of 0.1 (Schulze
et al. 2006), 0.29 (O’Mahony et al. 2002) and 0.42
(Leboyer et al. 1998), while affected siblings of
early-onset (AAO£21 years) probands were 4.5 times
more likely than others to have an early onset (Lin
et al. 2006). AAO was estimated to have a heritability
of 0.52 in 27 extended families ascertained for bipolar
disorder (Visscher et al. 2001). Episode frequency was
signiﬁcantly correlated among bipolar probands and
their affected relatives with major affective disorders
(ICC = 0.56) (Fisfalen et al. 2005), refuting a previously
reported much lower estimate of 0.15 which did not
survive multiple testing correction (O’Mahony et al.
2002). Other subphenotypes have been shown to be
familial in bipolar disorder, including psychotic symp-
toms, sleep disturbances, proportion of manic to de-
pressive episodes, polarity at illness onset, suicidality,
comorbidities (panic disorder, alcohol and substance
abuse), and the quality of social relations
(MacKinnon et al. 1997; Potash et al. 2001; O’Mahony
et al. 2002; Dikeos et al. 2004; Kassem et al. 2006;
Schulze et al. 2006; Lai et al. 2013).
Our study comes with some additional limitations.
First, episode count was retrospectively self-reported
during the SCAN interview without validation from
external sources; it may be subject to recall bias and
be inﬂuenced by the patient’s current mood state or
personality characteristics (neuroticism, histrionic
traits). Second, while maximal heritabilities of AAO
and episodicity were derived from phenotypic correla-
tions in a sample with familial MDD (DeNt siblings),
SNP heritabilities were assessed in the merged
RADIANT and GSK Munich sample where 54.4% of
subjects had positive family history of MDD in
ﬁrst-degree relatives; low power did not allow us to
recalculate SNP heritabilities for this speciﬁc subset.
Third, ICC estimates were calculated in DeNt siblings
suffering from recurrent MDD, and the SNP herita-
bility of episodicity was assessed in 2368 genotyped
cases with recurrent MDD; on the other hand, the
SNP heritability of AAO was assessed in 3468 cases,
of which 92% had recurrent MDD. Therefore, since
heritabilities of AAO and episodicity might be
different in familial v. non-familial MDD and in recur-
rent v. single episode forms, Table 4 should be inter-
preted with caution.
In conclusion, this study systematically investigated
the familiality of AAO and episodicity in a sample of
full siblings with recurrent MDD. Signiﬁcant familial-
ity of both was found; the strength of the familial effect
was moderate for AAO and low for episodicity. An es-
timate of the upper limit to the narrow-sense herita-
bility of the two subphenotypes was calculated from
ICC values. AAO is under stronger additive genetic
control than episodicity. We also estimated in unre-
lated MDD subjects the proportion of the variance of
AAO explained by common SNPs (SNP heritability)
with the GREML procedure in GCTA software.
Analysis was underpowered for calculating SNP heri-
tability of episodicity, conﬁrming the need for larger
samples. The statistical framework described here
could be useful in future analyses. Assuming there is
a substantial genetic basis for AAO and episodicity,
one could further explore their pleiotropic genetic cor-
relations with various other traits or conditions in
order to unravel additional aspects in the pathogen-
esis, onset and course of MDD.
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